Aroa Biosurgery Limited (ASX: ARX)
Health Care · Biotechnology · NZ
AU$0.57
-5.00% today · -10.9% 1Y
Aroa Biosurgery Limited (ASX: ARX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $141.33M and employs 273 people.
Over the last twelve months the share price has lost 10.9%, trading between 0.50 and 0.80.
Tweenvest scores Aroa Biosurgery Limited across four factors: quality 63/100, value 43/100, growth 90/100. Its strongest factor is growth.
ARX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $141.33M
- Revenue (TTM)
- $59.34M
- P/E
- 53.08
- EPS
- 0.01
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- AU$0.80
- 52-week low
- AU$0.50
- Avg volume (3M)
- —
- Shares outstanding
- 345.90M
- Employees
- 273
- Next earnings
- —
About Aroa Biosurgery Limited
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
- ISIN
- NZARXE0001S1
- Founded
- 2007
- Listed since
- Jul 24, 2020
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.